Evusheld

Subscribe to NPR's Up First Email

Officials boost access to a drug that can protect the immunocompromised from COVID-19

A box of Evusheld, an antibody therapy developed by pharmaceutical company AstraZeneca for the prevention of COVID-19 in immunocompromised patients, is seen in February at the AstraZeneca facility for biological medicines in Sweden Jonathan Nackstrand/AFP via Getty Images hide caption

toggle caption

Jonathan Nackstrand/AFP via Getty Images

Shots - Health News

Officials boost access to a drug that can protect the immunocompromised from COVID-19

July 28, 2022 • Evusheld, a course of injected antibodies, helps protect people with weak immune systems for up to six months. The government is making it available through pharmacies and individual providers.

Hospitals use a lottery to allocate scarce COVID drugs for the immunocompromised

Evusheld is a treatment authorized for prevention of COVID-19 in people who are seriously immunocompromised or who have had serious adverse reactions to COVID-19 vaccines. Peter Bostrom/AstraZeneca hide caption

toggle caption

Peter Bostrom/AstraZeneca

Shots - Health News

Hospitals use a lottery to allocate scarce COVID drugs for the immunocompromised

January 25, 2022 • So far the government has distributed nearly 400,000 doses of Evusheld, a new drug that protects against COVID-19. Some 7 million Americans could benefit from the drug right away.

Hospitals use a lottery to allocate scarce COVID drugs for the immunocompromised

Listen · 3:51 3:51

Download
Embed <iframe src="https://www.npr.org/player/embed/1075432400/1076116202" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">